Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B.

Usami E, Kimura M, Kanematsu T, Yoshida S, Mori T, Nakashima K, Matsuoka T, Yoshimura T, Mori H, Sugiyama T, Teramachi H.

Exp Ther Med. 2014 Apr;7(4):941-946. Epub 2014 Feb 11.

2.

Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study.

Okada N, Azuma M, Imanishi M, Zamami Y, Kirino Y, Nakamura T, Teraoka K, Abe M, Ishizawa K.

Clin Ther. 2018 Jan 2. pii: S0149-2918(17)31112-8. doi: 10.1016/j.clinthera.2017.12.006. [Epub ahead of print]

PMID:
29305017
3.

[Retrospective investigation on the cases treated with liposomal amphotericin B].

Yamagishi Y, Mikamo H.

Jpn J Antibiot. 2010 Oct;63(5):347-64. Japanese.

PMID:
21268407
4.

Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.

Yamazaki H, Kondo T, Aoki K, Yamashita K, Takaori-Kondo A.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):123-131. doi: 10.1016/j.diagmicrobio.2017.10.018. Epub 2017 Nov 7.

PMID:
29203252
5.

Analysis of Hypokalemia as a Side Effect of Liposomal Amphotericin in Pediatric Patients.

Kobayashi R, Keino D, Hori D, Sano H, Suzuki D, Kishimoto K, Kobayashi K.

Pediatr Infect Dis J. 2017 Sep 21. doi: 10.1097/INF.0000000000001802. [Epub ahead of print]

PMID:
28945677
6.

Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?

Ural AU, Avcu F, Cetin T, Beyan C, Kaptan K, Nazaroglu NK, Yalcin A.

Eur J Clin Pharmacol. 2002 Jan;57(11):771-3.

PMID:
11868798
7.

Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia.

Wazny LD, Brophy DF.

Ann Pharmacother. 2000 Jan;34(1):94-7. Review.

PMID:
10669191
8.

[Retrospective analysis of the safety of four hours administration of liposomal amphotericin B in patients with chronic necrotizing pulmonary aspergillosis].

Yatera K, Yamasaki K, Kozaki M, Shimauchi M, Kawanami T, Nagata S, Suzuki Y, Tokuyama S, Inoue N, Nishida C, Ishimoto H, Kawajiri T, Awaya Y, Tsuda T, Mukae H.

Jpn J Antibiot. 2011 Oct;64(5):311-8. Japanese.

PMID:
22428214
9.

Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children.

Sunakawa K, Tsukimoto I, Tsunematsu Y, Honda M, Iwai N, Maniwa T, Haigo H, Suzuki K, Mori T.

J Infect Chemother. 2012 Aug;18(4):456-65.

PMID:
22286407
10.

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.

Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE.

Br J Haematol. 1997 Sep;98(3):711-8.

PMID:
9332329
11.

Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules.

Bernardo JF, Murakami S, Branch RA, Sabra R.

Nephron. 1995;70(2):235-41.

PMID:
7566310
12.

[Evaluation of the efficacy of liposomal amphotericin B].

Iyama S, Murase K, Sato T, Kikuchi S, Sato Y, Kobune M, Takimoto R, Kato J.

Kansenshogaku Zasshi. 2010 Mar;84(2):182-6. Japanese.

PMID:
20420163
13.

Hypokalemia in a pediatric intensive care unit.

Singhi S, Marudkar A.

Indian Pediatr. 1996 Jan;33(1):9-14.

PMID:
8772944
14.

Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.

Annino L, Chierichini A, Anaclerico B, Finolezzi E, Norata M, Cortese S, Cassetta MI, Fallani S, Novelli A, Girmenia C.

Antimicrob Agents Chemother. 2013 Jun;57(6):2596-602. doi: 10.1128/AAC.00155-13. Epub 2013 Mar 25.

15.

Safety and efficacy of treatment with liposomal amphotericin B in elderly patients at least 65 years old with hematological diseases.

Ueda S, Miyamoto S, Kaida K, Chizuka A, Kojima R, Takano J, Ogasawara T, Miyamoto K, Miyakoshi S, Kanda Y.

J Infect Chemother. 2016 May;22(5):287-91. doi: 10.1016/j.jiac.2016.01.009. Epub 2016 Feb 19.

PMID:
26908230
16.

Hypokalemia in Chinese peritoneal dialysis patients: prevalence and prognostic implication.

Szeto CC, Chow KM, Kwan BC, Leung CB, Chung KY, Law MC, Li PK.

Am J Kidney Dis. 2005 Jul;46(1):128-35.

PMID:
15983966
17.
18.

[Liposomal-amphotericin B efficacy and safety].

Hamada Y, Komatsu T, Seto Y, Matsubara H, Kume H, Sunakawa K, Yago K.

Kansenshogaku Zasshi. 2010 Mar;84(2):193-8. Japanese.

PMID:
20420165
19.

Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.

Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL.

Diagn Microbiol Infect Dis. 2013 Jul;76(3):361-7. doi: 10.1016/j.diagmicrobio.2013.04.001.

PMID:
23774005
20.

Must we really fear toxicity of conventional amphotericin B in oncological patients?

Mayer J, Doubek M, Vorlìcek J.

Support Care Cancer. 1999 Jan;7(1):51-5.

PMID:
9926976

Supplemental Content

Support Center